CHERRY HILL, N.J.--(BUSINESS WIRE)--April 3, 2006--Mediscience Technology, Corp. (OTCBB:MDSC.OB - News) announced today: The Food and Drug Administration on March 29, 2006 approved as a “Non-significant risk device study the Company’s multi-center pilot study to establish the safety and parameters of efficacy of its proprietary Optical Biopsy Device (CD-R) for cancer detection of the cervix preliminary to a pivotal study” expected to bring this molecular algorithmic specific technology to market.
